Analyzing long-term survivors of aggressive solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to explore the characteristics of exceptional long-term survivors of solid tumors with poor prognosis, including pancreatic adenocarcinoma, glioblastoma IDH-wildtype, and extensive small-cell lung cancer. It will utilize a retrospective, multi-center approach to collect and analyze clinical records, imaging, and multi-omics data from patients who have survived significantly longer than expected. The goal is to identify biomarkers of resistance and survival that could lead to new therapeutic targets. Advanced technologies, including artificial intelligence, will be employed to interpret the complex data generated from these analyses.

Why it matters

Who can join: the full rules

Inclusion Criteria:

FOR SURVIVORS

* To be eligible the exceptional survivor patients must fulfill the following inclusion criteria:

  1. Adult patient (≥18 years old at diagnosis).
  2. Three distinct cohorts, one of patients harbouring metastatic pancreatic ductal adenocarcinoma, glioblastoma IDHwt, extensive small cell lung cancer.
  3. Long-term survival is defined as an exceptionally long survival ≥ 5 years from stage IV diagnosis for PDAC, extensive SCLC, and ≥ 3 years for GBM-IDHwt.
  4. Availability of at least one block sample and associated clinical annotations with following characteristics:

     * One block sample must be of sufficient quality and in sufficient quantity to perform multi-omic analyses, according to requirements specified in Lab manual
     * Any treatment prior to sample acquisition must be reported - all treatments accepted (standard / targeted);
     * Samples should be at least 5 years old for PDAC and SCLC and 3 years old for GBM

For CONTROL GROUPS :

* To be eligible the control patients must fulfill the following inclusion criteria:

  1. ≥18 years old at diagnosis.
  2. Three distinct cohorts, one of patients suffering from metastatic pancreatic ductal adenocarcinoma, one for glioblastoma, one for extensive small cell lung cancer.
  3. Paired to long-term survivors as mentioned in the methodology section
  4. Death or median overall survival with a variation of 10% before of beyond as reported in pivotal clinical trials in the specific type disease
  5. Availability of at least one tumor sample and associated clinical annotations with following characteristics:

     * Sample must be of sufficient quality and in sufficient quantity to perform multi-omic analyses
     * Any treatment prior to sample acquisition must be reported (treatment-naive samples should be preferred) - all treatments accepted (standard / targeted).

     Exclusion Criteria for both groups :
* Patient must not be enrolled if he/she fulfils one of the following non-inclusion criteria:

  1. \<18 years old at diagnosis.
  2. Hematological malignancy or solid tumors, which are not in the scope of tumor types, described in the inclusion criteria.
  3. Tumor sample not available or not reaching the required quality for multi-omic analyses.

Where it's running

• Gustave Roussy Cancer Campus, Grand Paris
  Villejuif, France Recruiting

Study contacts

• Principal investigator: Julieta Rodriguez, MD — Gustave Roussy, Cancer Campus, Grand Paris
• Study coordinator: Wolikow Nicolas, Master
• Email: nicolas@cure51.com
• Phone: 0033772042022

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cirtuvivint plus irinotecan for relapsed small-cell lung cancer

  This trial will test whether adding cirtuvivint to irinotecan helps people with relapsed small-cell lung cancer respond better and live longer.

  Recruiting Phase 1/2 Washington University School of Medicine · St Louis, Missouri · NCT07155200

• Testing NEO212 for treating certain brain tumors and metastases

  This study is testing a new treatment called NEO212 for people with certain types of brain tumors to see if it is safe and effective when combined with standard treatments.

  Recruiting at 8 sites Phase 1/2 Neonc Technologies, Inc. · Beverly Hills, California and 7 other locations · NCT06047379

• Hepatic artery infusion therapy for liver metastases after pancreatic/duodenal cancer surgery

  This study tests whether delivering chemotherapy directly to the liver via a pump can help people with pancreatic or duodenal cancer that has spread mainly to the liver after surgery and prior chemotherapy.

  Recruiting AdventHealth · Orlando, Florida · NCT07845617

• Tarlatamab in strong-performance-status small-cell lung cancer

  This trial tests whether tarlatamab can help people with extensive-stage small-cell lung cancer and poor health (ECOG 2) who have already had prior treatment.

  Recruiting at 8 sites Phase 2 AIO-Studien-gGmbH · Berlin and 7 other locations · NCT07803848

• Armored DLL3-SAVVYZ-IL18 CAR T cells for DLL3+ cancers

  Aims to see if DLL3-SAVVYZ-IL18 CAR T cells can be safely given to people with DLL3-positive cancers, including certain small cell lung cancers and other neuroendocrine tumors.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07783477

• Tarlatamab given under the skin vs by IV in extensive-stage small cell lung cancer after platinum therapy

  This trial tests whether subcutaneous tarlatamab works as well as the IV form for people with extensive-stage small cell lung cancer after platinum chemotherapy.

  Recruiting at 9 sites Phase 3 Amgen · Orlando, Florida and 8 other locations · NCT07778316

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.